Aytu Bioscience Inc  

(Public, OTCMKTS:AYTUW)   Watch this stock  
Find more results for NASDAQ:AYTU
-0.0296 (-41.93%)
Jan 19 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.04 - 0.04
52 week 0.04 - 0.30
Open 0.04
Vol / Avg. 5,454.00/20.00
Mkt cap 180,508.00
P/E     -
Div/yield     -
EPS -32.82
Shares 4.40M
Beta     -
Inst. own 10%
Feb 7, 2018
Q2 2018 Aytu BioScience Inc Earnings Release (Estimated) Add to calendar
Nov 9, 2017
Q1 2018 Aytu BioScience Inc Earnings Call
Nov 9, 2017
Q1 2018 Aytu BioScience Inc Earnings Release

Key stats and ratios

Q3 (Sep '17) 2017
Net profit margin -394.38% -698.67%
Operating margin -404.70% -624.70%
EBITD margin - -449.95%
Return on average assets -93.96% -114.43%
Return on average equity -328.93% -319.61%
Employees 1 -
CDP Score - -


373 Inverness Pkwy Ste 206
ENGLEWOOD, CO 80112-5898
United States - Map
+1-720-4376580 (Phone)
+1-302-6365454 (Fax)

Website links


Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company's pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men. The Company, through its wholly-owned subsidiary Nuelle, Inc., is focused on women’s sexual wellbeing and intimacy.

Officers and directors

Joshua R. Disbrow Chief Executive Officer, Director
Age: 41
David A. Green CPA Chief Financial Officer, Treasurer, Secretary
Age: 55
Jarrett T. Disbrow Chief Operating Officer
Michael Macaluso Director
Age: 66
Gary V. Cantrell Independent Director
Carl C Dockery Independent Director
Age: 53
John Donofrio Jr. Independent Director